Photo from wikipedia
Erythropoiesis‐stimulating agent (ESA) hyporesponsiveness is an important cause for the undertreatment of anaemia. A decrease in haemoglobin (Hb) levels was observed during the initial stage of the conversion from ESA… Click to show full abstract
Erythropoiesis‐stimulating agent (ESA) hyporesponsiveness is an important cause for the undertreatment of anaemia. A decrease in haemoglobin (Hb) levels was observed during the initial stage of the conversion from ESA to roxadustat. The study aims to investigate the effectiveness and safety of adding roxadustat to an ESA for the treatment of ESA‐hyporesponsive anaemia in patients on peritoneal dialysis (PD).
Keywords:
erythropoiesis stimulating;
hyporesponsive anaemia;
agent esa;
stimulating agent;
anaemia;
esa hyporesponsive
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!